A carregar...
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action t...
Na minha lista:
| Publicado no: | World J Gastroenterol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6010939/ https://ncbi.nlm.nih.gov/pubmed/29930467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v24.i23.2457 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|